Acelyrin (NASDAQ:SLRN) (NASDAQ:SLRN), formerly known as Soleno Therapeutics, is a clinical-stage specialty biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare endocrine and metabolic disorders. Since its founding, the company has focused on innovative controlled-release formulations designed to address conditions driven by hormonal dysregulation. The rebranding to Acelyrin in early 2022 underscores its renewed commitment to advancing treatments for orphan and underserved patient populations.
The company’s lead program centers on diazoxide choline controlled-release (DCCR), a novel therapy designed to activate ATP-sensitive potassium channels in the hypothalamus to help regulate appetite and metabolic processes. DCCR has been evaluated in clinical trials for Prader-Willi syndrome, where it has shown potential to reduce hyperphagia, improve behavior, and positively impact metabolic parameters. Beyond Prader-Willi, Acelyrin is exploring additional indications in rare and severe endocrine disorders that could benefit from its proprietary delivery platform.
Acelyrin conducts its research and clinical programs across North America and Europe, partnering with leading academic institutions, clinical sites, and patient advocacy organizations. These collaborations aim to optimize patient enrollment and ensure robust data collection, while ongoing interactions with regulatory agencies seek to streamline development pathways and facilitate timely access to new therapies for individuals affected by life-altering conditions.
The company is led by a management team with deep expertise in drug development, regulatory affairs, and commercialization within the rare disease space. Supported by a board of directors and a scientific advisory board comprising seasoned professionals in endocrinology and metabolic research, Acelyrin is positioned to translate its pipeline of novel treatments into meaningful clinical outcomes for patients worldwide.
